查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2011664

免疫腫瘤學檢測市場：2026-2032年全球市場預測（依技術類型、產品類型、檢體類型、最終用戶、適應症和應用分類）

Immuno Oncology Assays Market by Technology Type, Product, Sample Type, End User, Indication, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，免疫腫瘤學檢測市場價值將達到 83.3 億美元，到 2026 年將成長至 95.7 億美元，到 2032 年將達到 231.6 億美元，年複合成長率為 15.71%。

主要市場統計數據
基準年 2025 83.3億美元
預計年份：2026年 95.7億美元
預測年份 2032 231.6億美元
複合年成長率 (%) 15.71%

這是一本權威的入門書籍，概述了免疫腫瘤學檢測在研究、臨床開發和診斷應用案例中的戰略重要性和範圍。

目前免疫腫瘤學檢測技術正處於快速發展的生物學知識與日益精密的測量技術交會的階段。本概述介紹了該領域目前的重點工作，包括提高檢測的靈敏度和特異性、整合多組體學測量以及將實驗室發現轉化為臨床應用工具。此外，本報告還闡明了其目標：分析影響技術發展和商業化路徑的技術進步、產品差異化、檢體處理注意事項、終端用戶採用模式以及應用主導的用例。

全面概述了正在重塑檢測方法開發並加速其在轉化和臨床環境中應用的變革性技術、監管和商業性變化。

過去幾年，免疫腫瘤學檢測領域發生了翻天覆地的變化，重塑了其科學和商業性格局。單細胞解析度、多蛋白檢測和高通量定序的進步，共同擴展了可測量的免疫表現型範圍。同時，曾經主要用作初步研究工具的平台，也透過自動化、標準化和改進的品管措施，發展成為臨床級應用平台。

關稅趨勢的變化如何推動檢測採購和製造領域的供應鏈韌性、供應商多元化和本地化策略。

貿易政策的變化和關稅調整為營運全球供應鏈並向臨床和研究實驗室提供檢測服務的企業帶來了更大的複雜性。關稅趨勢正在影響設備和耗材的籌資策略，進而影響供應商多元化、區域庫存佈局和生產能力在地化等方面的決策。許多企業目前正在權衡跨國採購的營運成本與維持對少數全球供應商提供的特殊試劑和設備的取得管道所帶來的策略價值。

詳細的細分洞察揭示了技術平台、產品類型、檢體格式、最終用戶需求、適應症和應用如何相互作用，從而影響檢測優先順序。

細分市場層面的趨勢揭示了創新、應用和商業性競爭在技術類型、產品類型、樣本形式、終端用戶需求、適應症和應用領域中的交匯點。在技​​術領域，成熟的流式細胞技術等方法與質譜流式細胞儀和次世代定序並存，各自擁有獨特的優勢。傳統流式細胞技術仍然是表現型分析的基石，頻譜流式細胞技術擴展了多重測量能力，而質譜流式細胞儀則能夠進行高維度參數分析，從而實現詳細的免疫表現型分析。免疫分析方法也在不斷發展，從傳統的酵素連結免疫吸附試驗（ELISA）發展到能夠提供更廣泛的細胞激素譜和更高通量的多重免疫分析。次世代定序方法包括針對免疫相關位點的靶向測序、提供更廣泛基因組背景的全EXOME定序以及用於全面分析的全基因測序，每種方法都在不同的層面上平衡了深度、廣度和成本。

區域比較分析表明，美洲、歐洲、中東和非洲以及亞太地區的市場特徵如何影響產品引進、檢驗和商業化策略。

區域特徵對檢測方法的開發重點、商業化策略和合作模式有顯著影響。在美洲，產學合作以及成熟的臨床試驗基礎設施支持新型檢測方法快速進入臨床試驗，而美國的監管路徑和報銷趨勢則指導伴隨診斷​​的設計和檢驗。該地區創投公司和大型企業的投資活動通常會加速平台技術的規模化應用，而接近性大規模臨床網路則有利於進行廣泛的臨床檢驗專案。

公司層面的關鍵趨勢表明，平台模組化、試劑品質、策略夥伴關係和服務模式正在塑造競爭優勢和採取路徑。

產業參與者正透過結合獨特的診斷化學技術、整合平台和服務導向模式，建立差異化優勢。領先的儀器開發人員正投資於支援多種診斷工作流程的模組化架構，而試劑和耗材供應商則專注於抗體檢驗、試劑穩定性以及批間一致性，以降低下游數據的變異性。受託研究機構(CRO) 和專業服務供應商正成為缺乏內部能力進行大規模免疫監測和複雜組織檢測的機構的策略合作夥伴，提供包括檢測開發、樣本處理和資料分析在內的打包服務。

為了加速推廣應用，我們向行業領導者提供具體建議，重點關注嚴格的檢驗、以工作流程為中心的設計、供應鏈彈性、監管合作和數據協調。

該領域的領導者應優先採取一系列切實可行的步驟，將創新轉化為實際營運成果。首先，投資嚴格的檢測驗證流程，以確保分析性能、不同檢測點間的可重複性以及試劑的可追溯性。這種根本性的方法能夠降低下游臨床風險，並簡化與監管機構的合作。其次，在設計產品和服務時，應充分考慮最終使用者的工作流程。自動化、使用者友善的軟體以及與實驗室資訊系統的互通性能夠加速診斷和臨床環境中的應用。第三，透過對多家供應商進行認證、探索區域製造夥伴關係關係以及維護關鍵試劑的策略性庫存緩衝，增強供應鏈韌性，並減輕貿易政策變化和物流限制的衝擊。

我們透明的、專家主導的調查方法，結合了相關人員訪談、技術整合和迭代專家審查，確保了可操作和合理的見解。

本分析的調查方法透過整合與主要相關人員的對話、二手文獻以及跨領域專家評審，確保了研究的嚴謹性和相關性。主要資訊來源包括對科學領導者、實驗室管理人員和商業高管的訪談，從而獲得關於檢測性能、部署挑戰和應用促進因素的第一手觀點。這些定性研究結果與技術文獻和監管指南進行交叉比對，最終根據當前的最佳實踐和新興標準得出結論。

結論：整合技術進步、營運限制和策略要求，以確定哪些免疫腫瘤學檢測將具有臨床和商業性影響。

總之，免疫腫瘤學檢測正從主要用於探索的工具包轉變為一系列具有臨床意義且可擴展的解決方案，這些方案能夠對治療方法研發和患者照護產生重大影響。先進的多重檢測、單細胞解析度、定序深度和自動化技術的整合正在拓展可測量和可解釋的範圍，而供應鏈的實際情況和監管要求正在影響檢測方法的開發和部署。成功的策略需要在技術雄心和實際考慮（例如檢驗、可重複性和與最終用戶工作流程的整合）之間取得平衡。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：免疫腫瘤學檢測市場：依技術類型分類

  • 流式細胞技術
    • 常規流式細胞技術
    • 頻譜流式細胞技術
  • 免疫檢測
    • ELISA
    • 多重免疫檢測
  • 質譜流式細胞儀
  • 次世代定序
    • 目標面板
    • 全EXOME定序
    • 全基因組定序

第9章：免疫腫瘤學檢測市場：依產品分類

  • 消耗品
    • 探針和抗體
    • 試劑和試劑盒
  • 裝置
    • 自動化系統
    • 平台型設備

第10章：依樣本類型分類的免疫腫瘤學檢測市場

  • 血
  • 細胞株
  • 組織

第11章：免疫腫瘤學檢測市場：依最終用戶分類

  • 學術研究機構
    • 研究機構
    • 大學
  • 診斷檢查室
  • 醫院和診所
  • 製藥和生物技術

第12章：免疫腫瘤學檢測市場：依適應症分類

  • 乳癌
  • 血癌
  • 肺癌
  • 惡性黑色素瘤

第13章：免疫腫瘤學檢測市場：依應用領域分類

  • 生物標記發現
  • 伴隨診斷
  • 細胞激素分析
  • 免疫療法
  • 腫瘤微環境分析

第14章：免疫腫瘤學檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：免疫腫瘤學檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章：免疫腫瘤學檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國免疫腫瘤學檢測市場

第18章：中國腫瘤免疫檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Adaptive Biotechnologies Corporation
  • Agilent Technologies Inc.
  • Akoya Biosciences Inc.
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • DiaSorin SpA
  • Foundation Medicine Inc.
  • Guardant Health Inc.
  • Illumina Inc.
  • Invivoscribe Inc.
  • Merck KGaA
  • Meso Scale Diagnostics LLC
  • Myriad Genetics Inc.
  • NanoString Technologies Inc.
  • NeoGenomics Laboratories
  • PerkinElmer Inc.
  • Qiagen NV
  • Quanterix Corporation
  • Roche Holding AG
  • Siemens Healthineers AG
  • Standard BioTools Inc.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-43676CF42882

The Immuno Oncology Assays Market was valued at USD 8.33 billion in 2025 and is projected to grow to USD 9.57 billion in 2026, with a CAGR of 15.71%, reaching USD 23.16 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.33 billion
Estimated Year [2026] USD 9.57 billion
Forecast Year [2032] USD 23.16 billion
CAGR (%) 15.71%

An authoritative introduction framing the strategic importance and scope of immuno-oncology assays across research, clinical development, and diagnostic use cases

The immuno-oncology assays landscape sits at the intersection of rapidly advancing biological understanding and increasingly sophisticated measurement technologies. This introduction frames the field's contemporary priorities: improving assay sensitivity and specificity, integrating multi-omic readouts, and translating laboratory discoveries into clinically actionable tools. It also establishes the report's remit to analyze technology evolution, product differentiation, sample handling considerations, end-user adoption patterns, and application-driven use cases that shape development and commercialization pathways.

This section underscores why immuno-oncology assays are central to modern oncology research and therapeutic development. From early-stage biomarker discovery through companion diagnostics and immune monitoring in clinical trials, assays serve as the backbone of objective decision-making. Throughout the report, emphasis is placed on reproducibility, regulatory alignment, and operational scalability as determinants of whether a technique moves from exploratory use to routine deployment. The introduction closes by outlining how subsequent sections will provide strategic context across technological, commercial, and regional dimensions to support investor, developer, and practitioner decision-making.

A synthesis of the transformative technological, regulatory, and commercial shifts reshaping assay development and accelerating adoption across translational and clinical settings

The past several years have witnessed transformative shifts that reconfigure both the scientific and commercial contours of immuno-oncology assays. Advances in single-cell resolution, multiplexed protein detection, and high-throughput sequencing have converged to expand the range of measurable immune phenotypes. At the same time, platforms that once served primarily as research tools are evolving toward clinical-grade implementations through improved automation, standardization, and quality control practices.

Concurrently, the ecosystem supporting assay deployment is changing; partnerships between instrument manufacturers, reagent suppliers, and contract research organizations are becoming more strategic and vertically integrated. This trend accelerates when assay workflows are designed with end-user constraints in mind, such as limits on sample volume, turnaround time pressures in clinical settings, and the need for interoperable data outputs. Regulatory expectations are also evolving, pushing developers to demonstrate analytical validity, clinical relevance, and robust quality management systems earlier in development. Together, these shifts create an environment where technological innovation must be matched by operational rigor and clear pathways to adoption if new assay modalities are to realize their potential in research and patient care.

How evolving tariff dynamics are prompting supply chain resilience, supplier diversification, and localization strategies for assay procurement and manufacturing

Trade policy changes and tariff adjustments have introduced additional layers of complexity for organizations operating global supply chains and deploying assays across clinical and research laboratories. Tariff dynamics influence sourcing strategies for instruments and consumables, affecting decisions about supplier diversification, regional inventory staging, and the localization of manufacturing capabilities. Many organizations now weigh the operational costs of cross-border procurement against the strategic value of maintaining access to specialized reagents and instruments that may be available only from a limited set of global suppliers.

In response, stakeholders are adopting a range of mitigations. Some are re-evaluating supplier agreements and entering into longer-term contracts to stabilize pricing and availability. Others are accelerating qualification procedures for alternative suppliers and investing in local manufacturing partners or contract manufacturers to reduce exposure to tariff-induced cost volatility. Additionally, procurement and supply chain teams are collaborating more closely with R&D and clinical operations to prioritize critical components and design assays that are less dependent on single-source inputs. These adaptations aim to preserve continuity of research and clinical programs while maintaining compliance and cost-effectiveness in the face of shifting trade policies.

Detailed segmentation insights revealing how technology platforms, product types, sample formats, end-user needs, indications, and applications interact to shape assay prioritization

Segment-level dynamics reveal where innovation, adoption, and commercial tension intersect across technology types, product categories, sample formats, end-user needs, indications, and applications. Within technology, established modalities such as flow cytometry coexist with mass cytometry and next-generation sequencing, each offering distinct strengths. Conventional flow cytometry remains a workhorse for phenotyping while spectral flow cytometry extends multiplexing capacity, and mass cytometry enables very high parameter profiling for deep immune phenotyping. Immunoassay formats continue to evolve from traditional ELISA toward multiplex immunoassays that deliver broader cytokine panels and higher throughput. Next-generation sequencing approaches span targeted panels tailored to immune-related loci, whole exome sequencing that provides broader genomic context, and whole genome sequencing for comprehensive analyses, with each tier balancing depth, breadth, and cost considerations.

Product segmentation differentiates consumables from instruments, where consumables encompass probes, antibodies, reagents, and kits that must be optimized for lot-to-lot consistency and assay specificity, and instruments include both automated systems that support high-throughput workflows and platform-based instruments designed for flexible use across multiple assay types. Sample type considerations influence workflow design and assay selection; blood-based assays offer minimally invasive longitudinal monitoring, cell line workstreams drive mechanistic discovery, and tissue-based assays provide spatial and contextual information critical for tumor microenvironment analysis. End users present varying priorities: academic and research institutes, including both research institutes and universities, prioritize assay flexibility and novel readouts, diagnostic laboratories emphasize regulatory compliance and throughput, hospitals and clinics require rapid turnaround and clinical utility, and pharmaceutical and biotech organizations focus on assay reproducibility and integration into clinical trial workflows. Indication-specific needs shape validation strategies and selection criteria; assays for breast cancer, hematologic cancers, lung cancer, and melanoma each confront distinct tissue availability, biomarker signatures, and clinical endpoints. Application-driven segmentation-biomarker discovery, companion diagnostics, cytokine analysis, immune monitoring, and tumor microenvironment analysis-dictates assay performance thresholds and data interpretation frameworks, informing whether an approach is most suitable for exploratory research, diagnostic development, or clinical trial readouts.

Taken together, these segment dimensions illustrate that successful assay strategies are those that align technology choice, product design, and operational execution with specific sample contexts, end-user workflows, and therapeutic indications. Transitional investments in assay standardization, cross-platform data harmonization, and user-centric automation bridge the gap between promising methods and widespread adoption.

Comparative regional insights illustrating how Americas, Europe Middle East & Africa, and Asia-Pacific market characteristics influence adoption, validation, and commercialization strategies

Regional characteristics exert strong influence on assay development priorities, commercialization strategies, and collaborative landscapes. In the Americas, academic-industry partnerships and a mature clinical trials infrastructure support rapid translation of novel assays into trial settings, while U.S. regulatory pathways and reimbursement dynamics guide the design and validation of companion diagnostics. Venture and corporate investment activity in this region often accelerates the scaling of platform technologies, and proximity to large clinical networks enables extensive clinical validation programs.

Europe, the Middle East & Africa exhibits a heterogeneous landscape where regulatory harmonization efforts, cross-border research collaborations, and national healthcare systems create both opportunities and complexities. European centers of excellence frequently lead multicenter studies focused on immune profiling and tumor microenvironment characterization, but developers must account for diverse regulatory expectations and reimbursement frameworks across jurisdictions. The Middle East and Africa are experiencing growing investments in research capacity and clinical infrastructure, creating nascent demand for robust, scalable assays that can be deployed in centralized laboratories.

Asia-Pacific is marked by rapidly expanding research output, increasing clinical trial activity, and an emphasis on local manufacturing and capacity building. Several countries are prioritizing biotech and life science initiatives, fostering ecosystems that support assay innovation and localized production of reagents and instruments. The region also presents opportunities for tailored diagnostic strategies that reflect population-specific disease biology and healthcare delivery models. Across all regions, cross-border collaborations and digital data sharing initiatives are helping to standardize methodologies and accelerate dissemination of best practices.

Key company-level dynamics showing how platform modularity, reagent quality, strategic partnerships, and service models are shaping competitive advantage and adoption pathways

Industry participants are forging differentiated positions through a combination of proprietary assay chemistries, integrated platforms, and service-oriented models. Leading instrument developers are investing in modular architectures that support multiple assay workflows, while reagent and consumable suppliers are concentrating on antibody validation, reagent stabilization, and lot-to-lot consistency to reduce variability in downstream data. Contract research organizations and specialized service providers are becoming strategic partners for organizations that lack in-house capacity to run large-scale immune monitoring or complex tissue-based assays, offering assay development, sample processing, and data analysis as bundled services.

Collaborations between diagnostics companies and pharmaceutical sponsors are increasingly common, driven by the need for companion diagnostics that can stratify patients and support therapeutic approval pathways. At the same time, smaller innovators are carving niches by delivering highly multiplexed assays, advanced single-cell analytics, or streamlined automation aimed at specific clinical workflows. Cross-sector partnerships, including academic spin-outs and instrument-reagent co-development agreements, are central to advancing assay robustness and accelerating clinical validation. Overall, competitive dynamics emphasize interoperability, quality assurance, and the ability to provide end-to-end solutions that reduce the barriers for clinical and translational adoption.

Actionable recommendations for industry leaders focusing on validation rigor, workflow-centric design, supply chain resilience, regulatory engagement, and data harmonization to accelerate adoption

Leaders in the field should prioritize a set of pragmatic, actionable measures to convert innovation into operational impact. First, invest in rigorous assay validation pathways that address analytical performance, reproducibility across sites, and traceability of reagents. This foundational work reduces downstream clinical risk and simplifies regulatory engagement. Second, design product and service offerings with the end-user workflow in mind: automation, user-friendly software, and interoperability with laboratory information systems accelerate adoption in diagnostic and clinical environments. Third, strengthen supply chain resilience by qualifying multiple suppliers, exploring regional manufacturing partnerships, and maintaining strategic inventory buffers for critical reagents to mitigate disruptions from trade policy changes and logistical constraints.

Fourth, engage early with clinical and regulatory stakeholders to align validation plans with approval and reimbursement expectations. Fifth, cultivate partnerships with academic centers and CROs to support multicenter validation studies and to access diverse patient cohorts. Sixth, invest in data harmonization and bioinformatics expertise to deliver clinically interpretable outputs from complex multi-omic assays. Implementing these recommendations in a coordinated fashion enhances the likelihood that new assays will achieve both scientific credibility and practical utility across research and clinical settings.

A transparent, expert-driven research methodology combining stakeholder interviews, technical synthesis, and iterative expert review to ensure actionable and defensible insights

The research methodology underpinning this analysis integrates primary stakeholder engagement, secondary literature synthesis, and cross-functional expert review to ensure rigor and relevance. Primary inputs include interviews with scientific leaders, laboratory directors, and commercial executives who bring firsthand perspectives on assay performance, deployment challenges, and adoption drivers. These qualitative insights are triangulated with technical literature and regulatory guidance to ground conclusions in current best practices and emerging standards.

Analytical approaches emphasize comparative technology assessment, evaluation of product lifecycle considerations, and scenario-based exploration of supply chain and regulatory variables. Special attention is paid to reproducibility benchmarks, validation frameworks, and implementation barriers across academic, clinical, and commercial settings. Findings were iteratively reviewed by subject-matter experts to refine strategic implications and to ensure that recommendations are actionable for stakeholders pursuing assay development, commercialization, or clinical integration.

Conclusion synthesizing technological progress, operational constraints, and strategic imperatives that determine which immuno-oncology assays will achieve clinical and commercial impact

In conclusion, immuno-oncology assays are transitioning from a predominantly exploratory toolkit toward a set of clinically relevant, operationally scalable solutions that can materially influence therapeutic development and patient care. The convergence of enhanced multiplexing, single-cell resolution, sequencing depth, and automation is expanding what is measurable and interpretable, while supply chain realities and regulatory expectations are shaping how assays are developed and deployed. Successful strategies will balance technological ambition with pragmatic considerations of validation, reproducibility, and end-user workflow integration.

Looking ahead, organizations that invest in robust assay validation, cultivate strategic partnerships, and design solutions that address real-world clinical and laboratory constraints will be best positioned to convert scientific advances into measurable clinical and commercial value. The ability to harmonize data across platforms and to translate complex multi-dimensional readouts into clinically meaningful insights will be the defining capability for leaders in this space.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immuno Oncology Assays Market, by Technology Type

  • 8.1. Flow Cytometry
    • 8.1.1. Conventional Flow Cytometry
    • 8.1.2. Spectral Flow Cytometry
  • 8.2. Immunoassay
    • 8.2.1. Elisa
    • 8.2.2. Multiplex Immunoassay
  • 8.3. Mass Cytometry
  • 8.4. Next Generation Sequencing
    • 8.4.1. Targeted Panel
    • 8.4.2. Whole Exome Sequencing
    • 8.4.3. Whole Genome Sequencing

9. Immuno Oncology Assays Market, by Product

  • 9.1. Consumables
    • 9.1.1. Probes And Antibodies
    • 9.1.2. Reagents And Kits
  • 9.2. Instruments
    • 9.2.1. Automated Systems
    • 9.2.2. Platform Based Instruments

10. Immuno Oncology Assays Market, by Sample Type

  • 10.1. Blood
  • 10.2. Cell Lines
  • 10.3. Tissue

11. Immuno Oncology Assays Market, by End User

  • 11.1. Academic And Research Institutes
    • 11.1.1. Research Institutes
    • 11.1.2. Universities
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals And Clinics
  • 11.4. Pharmaceutical And Biotech

12. Immuno Oncology Assays Market, by Indication

  • 12.1. Breast Cancer
  • 12.2. Hematologic Cancers
  • 12.3. Lung Cancer
  • 12.4. Melanoma

13. Immuno Oncology Assays Market, by Application

  • 13.1. Biomarker Discovery
  • 13.2. Companion Diagnostics
  • 13.3. Cytokine Analysis
  • 13.4. Immune Monitoring
  • 13.5. Tumor Microenvironment Analysis

14. Immuno Oncology Assays Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immuno Oncology Assays Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immuno Oncology Assays Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Immuno Oncology Assays Market

18. China Immuno Oncology Assays Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Adaptive Biotechnologies Corporation
  • 19.7. Agilent Technologies Inc.
  • 19.8. Akoya Biosciences Inc.
  • 19.9. Becton Dickinson and Company
  • 19.10. Bio-Rad Laboratories Inc.
  • 19.11. Danaher Corporation
  • 19.12. DiaSorin S.p.A.
  • 19.13. Foundation Medicine Inc.
  • 19.14. Guardant Health Inc.
  • 19.15. Illumina Inc.
  • 19.16. Invivoscribe Inc.
  • 19.17. Merck KGaA
  • 19.18. Meso Scale Diagnostics LLC
  • 19.19. Myriad Genetics Inc.
  • 19.20. NanoString Technologies Inc.
  • 19.21. NeoGenomics Laboratories
  • 19.22. PerkinElmer Inc.
  • 19.23. Qiagen N.V.
  • 19.24. Quanterix Corporation
  • 19.25. Roche Holding AG
  • 19.26. Siemens Healthineers AG
  • 19.27. Standard BioTools Inc.
  • 19.28. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONVENTIONAL FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SPECTRAL FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MULTIPLEX IMMUNOASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MASS CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TARGETED PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PROBES AND ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REAGENTS AND KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY AUTOMATED SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PLATFORM BASED INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CELL LINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TISSUE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY UNIVERSITIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY HEMATOLOGIC CANCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COMPANION DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CYTOKINE ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNE MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TUMOR MICROENVIRONMENT ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 241. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 242. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 243. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 244. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 245. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 246. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 249. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 250. GCC IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 277. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 280. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 281. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 282. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 283. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 284. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 285. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 287. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 288. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 289. G7 IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 293. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 294. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 295. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 296. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 297. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 298. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 301. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 302. NATO IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. GLOBAL IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 309. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 310. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY CONSUMABLES, 2018-2032 (USD MILLION)
  • TABLE 311. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 312. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 314. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 315. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 316. UNITED STATES IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 317. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 318. CHINA IMMUNO ONCOLOGY ASSAYS MARKET SIZE, BY TECHNOLOGY TYPE, 2018-2032 (USD MILLION)

TABLE